NUC Price sensitive 24 Jul 2025, 2:51 PM

Quarterly Activities Report & Appendix 4C

Nuchev Ltd

Nuchev builds on initial Vietnam pipefill and enters Agency Agreement

Key points

  • Group revenue of $6.3m in Q4 FY25, up 167% from pcp
  • FY25 Group revenue of $22.8m, up 110% from pcp
  • Entered exclusive Sales Agency Agreement with Brauer and H&S Brands in Australia

Full summary

Nuchev Limited reported a record quarterly revenue of $6.3 million in Q4 FY25, up 167% from the previous corresponding period (pcp). Full-year FY25 Group revenue was $22.8 million, up 110% from pcp. The strong performance was driven by continued growth in the Oli6® Nutritional brand, with sales in ANZ, China CBEC and Vietnam up 93% pcp in Q4 FY25. The company also saw success in the Practitioner channel, with sales of $8.5 million in FY25. Additionally, Nuchev entered into an exclusive Sales Agency Agreement with Brauer and H&S Brands in Australia, which generated an incremental $0.1 million in revenue for the quarter. The company remains focused on driving the business to achieve breakeven, with the continued expansion into the Vietnam market and the Agency Agreement as important steps forward. Nuchev CEO Nathan Cheong commented that the company is excited by the opportunities for future growth and remains focused on sales growth through rapidly delivering new product development to enable the Group to consistently generate positive cashflows from operations.

Guidance

The company reported FY25 Group revenue of $22.8 million, up 110% from the previous financial year.

Outlook

Nuchev remains focused on driving the business to achieve breakeven, with the continued expansion into the Vietnam market and the Agency Agreement with Brauer and H&S Brands as important steps forward. The company is excited by the opportunities for future growth and remains focused on sales growth through rapidly delivering new product development.

Summary generated by a large language model. Please interpret with care.

Sign in for more about this company, including guidance changes and other insights.
Sign in